These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37775662)

  • 1. Design and Purification of Tag/Catcher AP205-Based Capsid Virus-Like Particle Vaccines.
    Aves KL; Sander AF
    Methods Mol Biol; 2024; 2720():127-141. PubMed ID: 37775662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved
    Martinez FG; Zielke RA; Fougeroux CE; Li L; Sander AF; Sikora AE
    Infect Immun; 2023 Dec; 91(12):e0024523. PubMed ID: 37916806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advantages and Prospects of Tag/Catcher Mediated Antigen Display on Capsid-Like Particle-Based Vaccines.
    Aves KL; Goksøyr L; Sander AF
    Viruses; 2020 Feb; 12(2):. PubMed ID: 32041299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-Head Comparison of Modular Vaccines Developed Using Different Capsid Virus-Like Particle Backbones and Antigen Conjugation Systems.
    Fredsgaard L; Goksøyr L; Thrane S; Aves KL; Theander TG; Sander AF
    Vaccines (Basel); 2021 May; 9(6):. PubMed ID: 34063871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Freeze-Drying of a Capsid Virus-like Particle-Based Platform Allows Stable Storage of Vaccines at Ambient Temperature.
    Aves KL; Janitzek CM; Fougeroux CE; Theander TG; Sander AF
    Pharmaceutics; 2022 Jun; 14(6):. PubMed ID: 35745873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
    Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
    Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capsid virus-like particle display improves recombinant influenza neuraminidase antigen stability and immunogenicity in mice.
    Kang H; Martinez MR; Aves KL; Okholm AK; Wan H; Chabot S; Malik T; Sander AF; Daniels R
    iScience; 2024 Jun; 27(6):110038. PubMed ID: 38883830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacterial superglue enables easy development of efficient virus-like particle based vaccines.
    Thrane S; Janitzek CM; Matondo S; Resende M; Gustavsson T; de Jongh WA; Clemmensen S; Roeffen W; van de Vegte-Bolmer M; van Gemert GJ; Sauerwein R; Schiller JT; Nielsen MA; Theander TG; Salanti A; Sander AF
    J Nanobiotechnology; 2016 Apr; 14():30. PubMed ID: 27117585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Efficacy of a Capsid Virus-like Particle-Based Vaccine Targeting IL-1β for Treatment of Allergic Contact Dermatitis.
    Goksøyr L; Funch AB; Okholm AK; Theander TG; de Jongh WA; Bonefeld CM; Sander AF
    Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization.
    Brune KD; Leneghan DB; Brian IJ; Ishizuka AS; Bachmann MF; Draper SJ; Biswas S; Howarth M
    Sci Rep; 2016 Jan; 6():19234. PubMed ID: 26781591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure of AP205 Coat Protein Reveals Circular Permutation in ssRNA Bacteriophages.
    Shishovs M; Rumnieks J; Diebolder C; Jaudzems K; Andreas LB; Stanek J; Kazaks A; Kotelovica S; Akopjana I; Pintacuda G; Koning RI; Tars K
    J Mol Biol; 2016 Oct; 428(21):4267-4279. PubMed ID: 27591890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.
    Wakabayashi MT; Da Silva DM; Potkul RK; Kast WM
    Intervirology; 2002; 45(4-6):300-7. PubMed ID: 12566713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface Cross-Linking by Macromolecular Tethers Enhances Virus-like Particles' Resilience to Mucosal Stress Factors.
    Ali A; Ganguillet S; Turgay Y; Keys TG; Causa E; Fradique R; Lutz-Bueno V; Chesnov S; Tan-Lin CW; Lentsch V; Kotar J; Cicuta P; Mezzenga R; Slack E; Radiom M
    ACS Nano; 2024 Jan; 18(4):3382-3396. PubMed ID: 38237058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
    Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
    Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A proof-of-concept study for the design of a VLP-based combinatorial HPV and placental malaria vaccine.
    Janitzek CM; Peabody J; Thrane S; H R Carlsen P; G Theander T; Salanti A; Chackerian B; A Nielsen M; Sander AF
    Sci Rep; 2019 Mar; 9(1):5260. PubMed ID: 30918267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model.
    Monroy-García A; Gómez-Lim MA; Weiss-Steider B; Hernández-Montes J; Huerta-Yepez S; Rangel-Santiago JF; Santiago-Osorio E; Mora García Mde L
    Arch Virol; 2014 Feb; 159(2):291-305. PubMed ID: 23990055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
    Sheng Y; Li Z; Lin X; Ma Y; Ren Y; Su Z; Ma G; Zhang S
    Vaccine; 2023 Jul; 41(33):4867-4878. PubMed ID: 37391312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenicity and immunogenicity of HA2 and M2e influenza virus antigens conjugated to norovirus-like, VP1 capsid-based particles by the SpyTag/SpyCatcher technology.
    Heinimäki S; Lampinen V; Tamminen K; Hankaniemi MM; Malm M; Hytönen VP; Blazevic V
    Virology; 2022 Jan; 566():89-97. PubMed ID: 34894525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.